Some health care workers who call themselves "Lyme literate" insist that chronic Lyme disease is frequently diagnosed and treated by primary care physicians. Others, however, including the American Academy of Pediatrics and the Infectious Diseases Society of America, state that there is no convincing biological evidence that chronic Lyme disease exists.
Many doctors are concerned with the potential dangers associated with the prolonged and intensive use of oral and intravenous antibiotics (the recommended treatment for chronic Lyme disease), such as blood clots and life threatening infections. A study soon to be published in The Journal of Pediatrics attempts to determine how often chronic Lyme disease is actually being diagnosed and treated.
Named for a community in Connecticut where it was first diagnosed, Lyme disease is a multi-system infection caused by the bacteria B. burgdoferi. Treatment typically includes a 10-28 day course of oral antibiotics. "Lyme literate" groups, such as the International Lyme and Associated Diseases Society (ILADS), define chronic Lyme disease as a debilitating illness caused by a persistent infection of B. burgdoferi; symptoms include fatigue, difficulty concentrating, headaches, and irritability. Treatment requires oral and/or intravenous antibiotic therapy that can last from several months to several years.
Dr. Michael Johnson, now at the Hospital of Saint Raphael in New Haven, and Dr. Henry Feder, of the University of Connecticut Health Center, attempted to determine how frequently Connecticut doctors were diagnosing and treating chronic Lyme disease. Of the 285 primary care physicians who responded to the survey, nearly one-half did not believe that chronic Lyme disease is a legitimate diagnosis, and 48% were undecided. Only 6 physicians—or 2.1%—diagnosed and treated patients for chronic Lyme disease. These 6 physicians treated patients for an average of 20 weeks with oral antibiotics; however, because these six physicians did not treat their patients with months to years of oral and/or intravenous antibiotics, they do not fit into the "Lyme literate" category.
Contrary to the assertions of the "Lyme literate" community, Dr. Feder does not believe intravenous antibiotic treatment is common practice. "The 6 physicians in our study who treated patients with chronic Lyme disease do not fit into the 'Lyme literate' group," he explains, "because they treated their patients for an average of 20 weeks—not months to years—and it does not appear that intravenous therapy was used." According to Dr. Feder, "Physicians who diagnose patients with chronic Lyme disease, and put these patients in harm's way with months to years of potentially dangerous antibiotics, are outliers." These findings call into question the claims of "Lyme literate" advocacy groups, like ILADS, that chronic Lyme disease is frequently diagnosed and treated by many primary care physicians.
Although the number of physicians diagnosing and treating patients with chronic Lyme disease may be small, their influence seems to be growing. "The 'Lyme literate' network has been pivotal in advocating legislation in multiple states requiring insurance companies to cover the costs of intravenous therapy for presumed chronic Lyme disease," Dr. Feder notes. The debate over chronic Lyme disease is likely to continue as insurance companies and legislative bodies become more involved.
The study, reported in "Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians" by Michael Johnson, MD and Henry Feder, Jr. MD, appears in The Journal of Pediatrics, DOI 10.1016/j.jpeds.2010.06.031, published by Elsevier.
Brigid Huey | EurekAlert!
Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University
ASU scientists develop new, rapid pipeline for antimicrobials
14.12.2017 | Arizona State University
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.
To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...
The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.
Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...
With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong
Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
14.12.2017 | Health and Medicine
14.12.2017 | Physics and Astronomy
14.12.2017 | Life Sciences